Drug Related Products: Perrigo Company (NYSE:PRGO), Auxilium Pharmaceuticals (NASDAQ:AUXL), LifeVantage Corp (NASDAQ:LFVN), USANA Health Sciences (NYSE:USNA)

Perrigo Company (NASDAQ:PRGO)’s stock had its “neutral” rating restated by Zacks in a research note issued to investors on Friday, Stock Ratings News reports. They currently have a $160.00 target price on the stock. Perrigo Company (NYSE:PRGO) stock performance was 0.87% in last session and finished the day at $148.27. Traded volume was 1.44million shares in the last session and the average volume of the stock remained 1.13million shares. The beta of the stock remained 0.30. Perrigo Company (NYSE:PRGO) insider ownership is 0.20%.

Biopharmaceutical company Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) stated on Monday that Swedish Orphan Biovitrum AB (publ) (Sobi) became the Market Authorisation Holder (MAH) for the former’s Xiapex (collagenase clostridium histolyticum) in 28 EU member countries, Norway and Iceland on 3 April 2014. Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) rose 0.15 percent to $26.30 Tuesday on volume of 1.21million shares. The intra-day range of the stock was $25.18 to $26.49. Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) has a market capitalization of $1.30billion.

Shawn Talbott, Ph.D the Global Chief Science Officer for LifeVantage Corporation (NASDAQ:LFVN), a maker of what are called “nutraceuticals.” Better, he says, is to let your food be your pharmacy. LifeVantage Corp (NASDAQ:LFVN)’s stock on Apr 08, 2014 reported a increase of 0.79% to the closing price of $1.27. Its fifty two weeks range is $1.10 -$2.68. The total market capitalization recorded $132.01million. The overall volume in the last trading session was 322.2K shares. In its share capital, LFVN has 103.92million outstanding shares.

USANA Health Sciences Inc (NASDAQ:USNA) was downgraded by analysts at Zacks from an outperform rating to a neutral rating. Zacks currently has $79.50 price target on the stock. On Tuesday, shares of USANA Health Sciences, Inc. (NYSE:USNA) advanced 4.67% to close the day at $79.19. Company return on investment (ROI) is 30.40% and its monthly performance is recorded as 7.74%. USANA Health Sciences, Inc. (NYSE:USNA) quarterly revenue growth is 7.16%.